Recent studies of HCC tumor xenografts in mice and in vitro established that engineered CAR-T cells targeting the glypican 3 (GPC3) molecule, highly expressed in HCC samples and absent in healthy liver samples, could attack and eliminate GPC3-positive HCC cells [99,100,101,102]. This evidence concerns the gene GPC3 and neoplasm.